Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

RiboX Therapeutics’ Circular RNA Therapy RXRG001 Gets FDA Green Light for Dry Mouth Clinical Trial

Fineline Cube Oct 28, 2024

RiboX Therapeutics, a Shanghai-based developer of circular RNA (circRNA) therapies, has announced that it has...

Company Drug

AstraZeneca’s Zoladex Receives NMPA Approval for Higher Dosage Form in Breast Cancer Treatment

Fineline Cube Oct 28, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a UK-based pharmaceutical giant, has announced that it has received...

Company Drug

MicuRx Pharmaceuticals’ Antibiotic MRX-5 Completes Successful Phase I Clinical Trial in Australia

Fineline Cube Oct 28, 2024

MicuRx Pharmaceuticals Inc. (SHA: 688373), a Sino-US pharmaceutical company, has announced the successful completion of...

Policy / Regulatory

NMPA’s CDE Prioritizes Marketing Filings for Innovative Drugs with Priority Review Status

Fineline Cube Oct 28, 2024

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) released a...

Company Medical Device

Wantai Biological’s P85 Ab Detection Kit Receives NMPA Approval for Nasopharyngeal Carcinoma Screening

Fineline Cube Oct 28, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, announced last...

Company Drug

Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China

Fineline Cube Oct 28, 2024

The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on...

Company Deals

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania

Fineline Cube Oct 28, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in...

Company Deals

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development

Fineline Cube Oct 28, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...

Company Deals Drug

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS

Fineline Cube Oct 28, 2024

LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...

Company Drug

Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications

Fineline Cube Oct 28, 2024

Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the...

Company Drug

BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option

Fineline Cube Oct 28, 2024

BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced...

Company Drug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

Fineline Cube Oct 28, 2024

RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation...

Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports

Fineline Cube Oct 28, 2024

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Drug

RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China

Fineline Cube Oct 27, 2024

RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation...

Company Medical Device

Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment

Fineline Cube Oct 26, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced...

Company Drug

Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center

Fineline Cube Oct 26, 2024

On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration...

Company

TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs

Fineline Cube Oct 26, 2024

TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...

Policy / Regulatory

Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024

Fineline Cube Oct 25, 2024

The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...

Company Drug

BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy

Fineline Cube Oct 25, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...

Company

Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion

Fineline Cube Oct 25, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...

Posts pagination

1 … 285 286 287 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.